AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

The trial is evaluating Datroway (datopotamab deruxtecan) versus the investigator’s choice of chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribulin) in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.

The trial included patients whose tumors did not express PD-L1 as well as patients with PD-L1 expressing tumors who could not receive immunotherapy due to prior exposure in early-stage disease, comorbidities or immunotherapy not being accessible in their geography.

Also Read: AstraZeneca Moves From ADRs To NYSE Listing

Data

Datroway demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of ...